Dallas, Texas 02/04/2014 (FINANCIALSTRENDS) – In a recent announcement made by ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) stated that the company’s Chief Operating officer (CEO) Mr. Andrew Gengos will present the company’s business update and overall review on 10th February, 2014. The review and business report will be presented at Waldorf Astoria Hotel in New York. You can also access the live audio telecast of the entire proceedings though their official website that is imuc.com.
Recently company conducted a clinical trial of phase II level of one of its leading products called as ICT-107. This lead product is basically a dendrite cell based vaccine that targets different tumors which are associated with antigens for glioblastoma. Immuno Cellular Therapeutics Ltd have also got plans to come up with ICT-121 which is special dendrite cell based vaccine that targets CD-133 and ICT-140 which is also another special dendrite cell based vaccine that targets cancer stem cells and ovarian cancer antigens.
Something about Immuno Cellular Therapeutics Ltd
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) is clinical stage company that is based in Los Angeles in United States of America. The company is responsible for developing immune based advanced therapies and the area of specialization are brain and different types of cancer treatments.
Recently the company also provided updates on its current year milestones and corporate strategies. As per them 2013 was a very fruitful and eventful year and 2014 is going to be much bigger as they are focusing on advancing their pipeline of different cancer vaccines. They are also committed on delivering their best to their clients and are pretty confident about their clinical programs which they think are quite meaningful and therapeutic. The company is also quite confident as they have got all the needed resources with them and are certainly going to achieve their goals in the cancer immunotherapy field.